The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
Suitability of Oral Formulations Available to Children at the Time of Pediatric Labeling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdel-Rahman Susan M, Avant Debbie A, Burckart Gilbert J
Аннотация
BACKGROUND: The pediatric drug development landscape has experienced major shifts, largely in response to legislative and regulatory initiatives. However, associated laws and guidance documents fail to mandate the manufacture of pediatric formulations for commercial marketing post-regulatory approval. This study explores the nature of commercial products available at the time of pediatric labeling.
METHODS: All orally administered drugs for which labeling changes were made from 1998-2024 were evaluated. Characteristics of each drug's commercially marketed formulation(s) at the time of labeling were identified using product labeling (Drugs@FDA), Drugs.com, and DailyMed.
RESULTS: During the timeframe reviewed, there were 611 unique labeling changes representing 425 unique drugs available as 567 commercially marketed formulations. Of these drugs, 188 were marketed with pediatric-friendly (PF) formulations. The remainder were available only as solid oral dosage forms. For 329 pediatric labeling changes (53.8%), the only commercially marketed formulation was a solid oral dosage form, in many cases at sizes exceeding reasonable thresholds for the age group. For the remaining 282 labeling changes, a PF formulation was available alone or as a companion to the adult formulation. Among the PF formulations, 62% were suited to direct administration (liquid, orodispersible tablet, chewable/paste, transmucosal) while the remainder required manipulation (i.e. powder/granule, sprinkle/pellet, dispersible tablet). Three-fourths of the PF formulations incorporated flavorings and aromas though 13% failed to report the use of sweeteners.
CONCLUSIONS: Less than complete access to PF formulations requires attention if we are to maximize the provision of suitable pharmacotherapy for pediatric patients.
METHODS: All orally administered drugs for which labeling changes were made from 1998-2024 were evaluated. Characteristics of each drug's commercially marketed formulation(s) at the time of labeling were identified using product labeling (Drugs@FDA), Drugs.com, and DailyMed.
RESULTS: During the timeframe reviewed, there were 611 unique labeling changes representing 425 unique drugs available as 567 commercially marketed formulations. Of these drugs, 188 were marketed with pediatric-friendly (PF) formulations. The remainder were available only as solid oral dosage forms. For 329 pediatric labeling changes (53.8%), the only commercially marketed formulation was a solid oral dosage form, in many cases at sizes exceeding reasonable thresholds for the age group. For the remaining 282 labeling changes, a PF formulation was available alone or as a companion to the adult formulation. Among the PF formulations, 62% were suited to direct administration (liquid, orodispersible tablet, chewable/paste, transmucosal) while the remainder required manipulation (i.e. powder/granule, sprinkle/pellet, dispersible tablet). Three-fourths of the PF formulations incorporated flavorings and aromas though 13% failed to report the use of sweeteners.
CONCLUSIONS: Less than complete access to PF formulations requires attention if we are to maximize the provision of suitable pharmacotherapy for pediatric patients.